Kura Oncology Inc., a clinical-stage biopharmaceutical company, announced on August 4, 2025, that its Compensation Committee has granted inducement awards consisting of nonstatutory stock options to thirty-five new employees. The awards, approved under the Company's 2023 Inducement Option Plan, allow these employees to purchase a total of 646,700 shares of common stock at an exercise price of $6.02 per share, the closing price on August 1, 2025. The stock options will vest over a period of four years, with 25% vesting after one year and the remaining shares vesting monthly over the next 36 months, contingent on the employees' continued service with the company.